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Objective: To determine the cost-effectiveness of
arthroscopic surgery in addition to non-operative
treatments compared with non-operative treatments
alone in patients with knee osteoarthritis (OA).
Design, setting and participants: We conducted
an economic evaluation alongside a single-centre,
randomised trial among patients with symptomatic,
radiographic knee OA (KL grade ≥2).
Interventions: Patients received arthroscopic
debridement and partial resection of degenerative knee
tissues in addition to optimised non-operative therapy,
or optimised non-operative therapy only.
Main outcome measures: Direct and indirect costs
were collected prospectively over the 2-year study
period. The effectiveness outcomes were the Western
Ontario McMaster Osteoarthritis Index (WOMAC) and
quality-adjusted life years (QALYs). Cost-effectiveness
was estimated using the net benefit regression
framework considering a range of willingness-to-pay
values from the Canadian public payer and societal
perspectives. We calculated incremental cost-
effectiveness ratios and conducted sensitivity analyses
using the extremes of the 95% CIs surrounding mean
differences in effect between groups.
Results: 168 patients were included. Patients
allocated to arthroscopy received partial resection and
debridement of degenerative meniscal tears (81%)
and/or articular cartilage (97%). There were no
significant differences between groups in use of non-
operative treatments. The incremental net benefit was
negative for all willingness-to-pay values. Uncertainty
estimates suggest that even if willing to pay $400 000
to achieve a clinically important improvement in
WOMAC score, or ≥$50 000 for an additional QALY,
there is <20% probability that the addition of
arthroscopy is cost-effective compared with non-
operative therapies only. Our sensitivity analysis
suggests that even when assuming the largest
treatment effect, the addition of arthroscopic surgery
is not economically attractive compared with non-
operative treatments only.
Conclusions: Arthroscopic debridement of
degenerative articular cartilage and resection
of degenerative meniscal tears in addition to non-
operative treatments for knee OA is not an
economically attractive treatment option compared with
non-operative treatment only, regardless of willingness-
to-pay value.
Trial registration number: NCT00158431.
Strengths and limitations of this study
▪ This randomised trial-based economic evaluation
prospectively collected clinical effectiveness and
cost measures, including indirect patient-
reported costs, and directly elicited utility scores
from patients over a 2-year follow-up with
minimal loss to follow-up or crossovers.
▪ Our estimation of cost-effectiveness over a range
of willingness-to-pay values, investigation of
patient subgroups, and analysis of uncertainty
suggests that arthroscopy is not cost-effective
compared with non-operative care, as the add-
itional costs of surgery are not offset by
decreases in other direct or indirect costs asso-
ciated with knee OA.
▪ These results add important economic data to
the existing clinical evidence refuting the value of
arthroscopic debridement and resection of
degenerative knee tissues.
▪ The present results do not describe the cost-
effectiveness of knee arthroscopy beyond 2 years
of surgery; however, previous research consist-
ently shows that any small additional benefits
observed with arthroscopic surgery for degen-
erative knee conditions diminish by 1 year, sug-
gesting it is unlikely for arthroscopy to become
cost-effective as time progresses.
▪ As the present study was designed to evaluate
the cost-effectiveness of arthroscopy for patients
with knee OA, conclusions about the cost-
effectiveness of one non-operative treatment
compared with another (including sham), or
among patients without radiographic signs of OA
should not be drawn from the present data.
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Osteoarthritis (OA) of the knee is a leading cause of dis-
ability and healthcare use globally, and the substantial
economic burden is expected to grow.1 2 Knee OA is a
progressive condition that affects the whole joint, includ-
ing degenerative changes to the menisci, bone and
hyaline articular cartilage.3 4 Clinical practice guidelines
for managing knee OA consistently recommend non-
operative therapies as first-line treatments,5–9 yet recom-
mendations are less clear for the additional role of
arthroscopic surgical interventions such as trimming
meniscal tears to a stable rim (ie, partial resection),
smoothing articular surfaces (ie, debridement) and
removing loose bodies and/or osteophytes; procedures
that are still widely used to treat these degenerative joint
changes.
We previously conducted a randomised controlled
trial evaluating the effectiveness of arthroscopic surgery
in addition to optimised physical and medical therapy
among patients with symptomatic, radiographic knee
OA over a 2-year period.10 Results showed that arthros-
copy provided no additional benefit beyond 3 months
from surgery. Similarly, additional randomised trials
involving different intervention strategies and increas-
ingly restrictive eligibility criteria have also evaluated
arthroscopic surgery for degenerative changes in the
knee. These trials include arthroscopy compared with
sham surgery in patients with moderate-to-severe radio-
graphic OA,11 arthroscopic partial meniscectomy com-
pared with physical therapy and exercise in patients with
mild-to-moderate radiographic OA,12 13 and arthro-
scopic partial meniscectomy compared with non-
operative management14 15 or to sham surgery16 in
patients with degenerative meniscal tears and no radio-
graphic evidence of OA. Meta-analyses of the existing
evidence conclude that the additional benefit observed
after arthroscopy compared with non-operative interven-
tions is limited in time and absent at 1–2 years after
surgery.17 18
Despite this evidence, arthroscopic knee procedures
are still commonly performed. While administrative data
suggest rates of arthroscopy for knee OA are declining,
the number of procedures performed annually remains
high and the rate of arthroscopies to treat meniscal
tears, a common feature of knee OA,3 has remained the
same or increased.19–26 Accordingly, the role of arthro-
scopic surgery for treating degenerative knee conditions
remains highly debated.27–29
Although studies demonstrating a lack of clinical
effectiveness may suggest an economic evaluation is
unnecessary, many authors strongly caution against aban-
doning the procedure, stating the improvements
observed after surgery despite being similar to non-
operative treatments or to sham treatments are clinically
important and considered cost-effective nonethe-
less.27 28 30–32 Therefore, it is clear that evidence regard-
ing the cost-effectiveness of knee arthroscopy would be
valuable and analysis of the existing trial-based economic
data is warranted. The purpose of the present study was
to determine the cost-effectiveness of arthroscopic
surgery in addition to non-operative treatments com-




The present data were collected as part of our previ-
ously reported single-centre, randomised controlled
trial.10 Patients with symptomatic, radiographic knee
OA were randomly assigned to knee arthroscopy in add-
ition to optimised physical and medical therapy, or to
optimised physical and medical therapy only. Patients
were evaluated at baseline and 3, 6, 12, 18 and
24 months after the initiation of treatment. The proto-
col was approved by our institution’s research ethics
board, and all participants gave written informed
consent.
Optimised physical and medical therapy included a
1 h physical therapy session once a week for 12 consecu-
tive weeks, an individualised home exercise programme,
and education from the local Arthritis Society.33 Patients
reviewed their medical treatment plans with their ortho-
paedic surgeon, optimised according to an evidence-
based treatment algorithm consistent with published
guidelines.34
Patients in the surgery group received arthroscopy
within 6 weeks of randomisation. The specific surgical
procedures have been previously described.10 Patients
followed the same optimised physical and medical
therapy programme as those in the non-operative group,
beginning within 7 days following surgery.
Outcome measures
We conducted our cost-effectiveness analyses using two
separate patient-reported outcomes as our measure of
effectiveness. First, we used the Western Ontario
McMaster Osteoarthritis Index (WOMAC) total score at
the 2-year follow-up (the primary outcome from the ran-
domised trial). Total scores can range from 0 to 2400,
with higher scores indicating increased pain and stiff-
ness, and decreased physical function.35–37 We rescaled
the scores so that a higher number indicated a better
outcome. Published data suggested similar patients typic-
ally have a total WOMAC score of 1000 points.38 We con-
sidered a 20% improvement from this score (about 200
points) as clinically important.10
Our second effectiveness measure was quality-adjusted
life years (QALYs).39 40 We calculated QALYs using the
Standard Gamble technique.41 The Standard Gamble is
a health utility measure, with scores ranging from 0.0
(death) to 1.0 (perfect health). QALY is calculated as
the product of the utility score and the duration of the
corresponding health state. We report QALY over the
2-year study time period.
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We used the average procedure cost from the Ontario
Case Costing Initiative42 to obtain the direct costs of
each procedure including equipment, operating room
costs, and laboratory or other medical tests during the
procedure. We used the current surgeon billing fee for
each procedure listed in the Ontario Schedule of
Benefits.43
Non-operative care
We recorded the number of physical therapy sessions
attended for each patient. We used the rate per session
provided by a local physical therapy clinic. We also
recorded any medication use, including both
over-the-counter and prescription pain or anti-
inflammatory drugs, hyaluronic acid injections or other
medical treatment for knee OA. Unit costs for drugs
were obtained from the Ontario Drug Benefit
Formulary.44 Patients reported the amount paid for any
aids purchased for the study knee, such as orthotics,
crutches or braces.
Other healthcare costs
At each of the 3, 6, 12, 18 and 24 months of follow-up
visits, we recorded healthcare resource use associated
with the study knee including inpatient hospitalisations,
physical therapy, medication use (prescription and
over-the-counter), assistive devices, employment time
lost, and homemaking or volunteer time lost.
We estimated the total cost for each patient over the
entire study period. All costs are presented in 2014
Canadian dollars.
Statistical analysis
We conducted a cost-effectiveness analysis from both the
Canadian healthcare payer and societal perspectives.
The payer perspective includes direct costs covered by
the publicly funded system, including hospital,
procedure-related, clinician and provider time, tests, pro-
cedures or surgeries, and medications for patients on
disability or aged 65 years and older. In addition to the
healthcare system costs, the societal perspective also
includes any out-of-pocket costs to the patient (such as
physical therapy, medication or assistive devices not
covered by the provincial insurance plan), and indirect
costs such as time involved with appointments, and time
off employment, homemaking or caregiving activities as
a result of the intervention.
Net benefit regression
The net benefit regression (NBR) framework45 provides
an estimate of cost-effectiveness by considering the
incremental cost and effect on an intervention in add-
ition to the maximum acceptable willingness-to-pay
(WTP) per unit of health gain; in this case, WTP refers
to the amount one is willing to spend for an additional
improvement on the WOMAC score, or for an additional
QALY gained. An intervention is cost-effective if the
incremental net benefit (INB) is greater than zero.
We conducted two separate NBR models, the first
using the WOMAC total score, and the second using
QALYs as the measure of effectiveness. The WTP value
was varied between $0 and $100 000. Although we
anticipated that the randomised allocation of partici-
pants would result in an equal distribution of baseline
characteristics between groups, the NBR method pro-
vides a means to adjust for any potentially confound-
ing factors and therefore allows greater statistical
efficiency and provides a more precise estimate of the
INB.
We included the following covariates in our models:
baseline WOMAC score, baseline utility (for the QALY
model), radiographic severity of knee OA (Kellgren-
Lawrence grade 2, or greater than 2), age and body
mass index. Significant covariates from our regression
model were also included as interaction terms.
Statistical uncertainty was characterised using 95% CIs,
and visually displayed using the cost-effectiveness plane,
and cost-effectiveness acceptability curves (CEAC).46 We
used non-parametric bootstrapping to draw 1000 incre-
mental cost-effectiveness ratio (ICER) estimates from the
original sample, and plotted them on the cost-
effectiveness plane. The CEAC demonstrates the prob-
ability of cost-effectiveness at various WTP values.
Subgroup analysis
We repeated the two subgroup analyses performed in
the original trial, among the two groups of patients that
were hypothesised to derive greater benefit from
surgery: (1) patients with less severe radiographic
disease (KL grade 2), and (2) patients reporting mech-
anical symptoms of catching and/or locking.10
ICER, incremental cost-utility ratio and sensitivity analysis
We also considered the value of arthroscopy by calculat-
ing the ICERs. Further, we conducted a sensitivity ana-
lysis by using either extreme of our CI surrounding the
mean difference in WOMAC scores and QALY to esti-
mate ICER and incremental cost-utility ratio (ICUR)
values that assumed the highest possible treatment effect
observed in our sample, favouring either added arthros-
copy or non-operative treatments only.
RESULTS
A total of 168 patients were included (88 arthroscopy
group and 80 non-operative group; figure 1). Baseline
characteristics of the study participants were similar
between groups (table 1). Patients allocated to the arth-
roscopy group received debridement of degenerative
articular cartilage (97%), partial resection of degenera-
tive meniscal tears (81%), excision of osteophytes (9%)
and removal of loose bodies (14%). Non-operative
treatment included medical therapy (non-steroidal
anti-inflammatory drugs, acetaminophen, chondroitin
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sulfate or glucosamine, hyaluronic acid injection), phys-
ical therapy and bracing. There were no significant dif-
ferences in non-operative treatment between groups
(table 1).
There was a statistically significant difference between
groups in mean costs from both the healthcare payer
and societal perspectives (table 2). The mean difference
between groups in WOMAC scores at 24 months was
small (favouring the surgery group) and not statistically
significant (mean difference=15.69 (−198.58 to 166.98),
p=0.87). The mean difference between groups in QALY
scores was also small (favouring the non-operative
treatments only group) and not significantly different




The INB was negative for all WTP values, from both the
healthcare payer and societal perspectives, indicating
that the addition arthroscopic surgery is not cost-
effective compared with non-operative treatments only
(table 3).
Model 2: QALY
When using QALYs as the outcome, the INB estimate
was also negative at all WTP values, further suggesting
that the addition arthroscopic surgery is not cost-
effective compared with non-operative treatments only
(table 3).
Figure 1 Participant flow diagram.
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Arthroscopy was also not cost-effective in terms of both
WOMAC and QALY in the subgroup of patients with less
severe disease (Kellgren-Lawrence grade 2) and patients
reporting mechanical symptoms of catching and/or
locking from both cost perspectives at all values of WTP.
ICER, ICUR and sensitivity analysis
The ICER was $140.94 (societal), or $120.83 (payer) per
one-point improvement on the 2400 point WOMAC
total score, translating to $28 188 (societal) and $24 166
(payer) for a clinically important improvement (200
points). The ICUR was equal to −$110 569 (societal) or
−$94 792.50 (payer) per QALY gained, where the nega-
tive value indicates paying more for a worse outcome
(ie, the added surgery is dominated by non-operative
treatments only).
The results of our sensitivity analysis using either
extreme of our CIs suggested that, from the societal per-
spective, to achieve a clinically important improvement






Male—n (%) 34 (39) 23 (28)
Age (years)* 58.3±9.8 60.5±9.9
Body mass index† 31.6±6.6 30.2±6.4
Kellgren-Lawrence grade—n (%)‡
2 42 (48) 34 (42)
3 41 (47) 42 (53)
4 5 (6) 4 (5)
Symptoms of catching or locking—n (%) 43 (49) 37 (46)
WOMAC total score* 1222.9 (478.2) 1354.1 (545.5)
SG utility score 0.79 (0.22) 0.80 (0.21)
Non-operative treatment—n (%)
Medical therapy
Non-steroidal anti-inflammatory drugs 53 (58) 48 (56)
Acetaminophen 53 (58) 43 (50)
Chondroitin sulfate or glucosamine 28 (30) 25 (29)
Hyaluronic acid injection 39 (42) 33 (38)
Physical therapy§ 9.3±5.1 8.0±5.7
Use of brace 3 (3) 5 (6)
Surgical treatment—n (%)
Debridement of articular cartilage 83 (97)
Debridement or partial resection of meniscus 70 (81)
Excision of osteophytes 8 (9)
Removal of loose bodies 12 (14)
*Mean (SD).
†Body mass index is the weight in kilograms divided by the square of the height in metres.
‡Scale that evaluates the radiographic severity of osteoarthritis.
§Average number of physical therapy sessions attended in the first 3 months since randomisation.
SG, Standard Gamble; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Table 2 Cost and effect outcomes
Surgery* Non-operative* Incremental difference†
WOMAC
Baseline 1222.91 (478.16) 1355.26 (548.92) −132.35 (−24.58 to 289.29), 0.10
24-month 1526.45 (623.83) 1510.77 (570.21) 15.69 (−198.35 to 166.98), 0.87
Utility
Baseline 0.79 (0.22) 0.80 (0.21) 0.01 (−0.06 to 0.07), 0.85
24-month 0.84 (0.23) 0.86 (0.16) 0.02 (−0.04 to 0.08), 0.47
QALY 1.64 (0.40) 1.66 (0.30) −0.02 (−0.09 to 0.13), 0.72
Cost‡
Healthcare payer perspective 2633.25 (574.43) 737.40 (542.93) 1895.85 (1716.13 to 2075.57), <0.01
Societal perspective 3825.60 (1443.48) 1614.22 (1784.94) 2211.38 (1716.04 to 2706.51), <0.01
*Mean (SD).
†Mean difference between groups (95% CI), p value.
‡2014 Canadian dollars.
QALY, quality-adjusted life year; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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Incremental net benefit 95% CI, p value Incremental net benefit 95% CI, p value
0 −1179.20 (386.56) −1942.58 to −415.82, <0.01 −1670.507 (662.18) −2978.30 to −362.71, 0.01
1500 −352418.73 (332804.27) −1009643.31 to 304805.85, 0.29 −369151.74 (334686.56) −1030156.42 to 291852.95, 0.27
2000 −469498.57 (443753.31) −1345826.20 to 406829.05, 0.29 −491645.48 (446248.44) −1372984.45 to 389693.49, 0.27
2500 −586578.42 (554702.36) −1682009.13 to 508852.29, 0.29 −614139.22 (557810.37) −1715812.60 to 487534.16, 0.27
5000 −1171977.63 (1109447.72) −3362923.98 to 1018968.72, 0.29 −1226607.94 (1115620.38) −3429953.97 to 976738.10, 0.27
10 000 −2342776.07 (2218938.56) −6724753.89 to 2039201.76, 0.29 −2451545.36 (2231240.70) −6858237.29 to 1955146.56, 0.27
20 000 −4684372.93 (4437920.28) −13448413.80 to 4079667.94, 0.29 −4901420.22 (4462481.46) −13714804.20 to 3911963.77, 0.27
30 000 −7025969.80 (6656902.01) −20172073.70 to 6120134.15, 0.29 −7351295.08 (6693722.26) −20571371.20 to 5868871.04, 0.27
40 000 −9367566.66 (8875883.74) −26895733.70 to 8160600.36, 0.29 −9801169.94 (8924963.07) −27427938.20 to 7825598.33, 0.27
50 000 −11709163.50 (11094865.47) −33619393.60 to 10201066.58, 0.29 −12251044.80 (11156203.89) −34284505.20 to 9782415.63, 0.27
60 000 −14050760.40 (13313847.20) −40343053.60 to 12241532.79, 0.29 −14700919.70 (13387444.70) −41141072.20 to 11739232.93, 0.27
70 000 −16392357.30 (15532828.94) −47066713.50 to 14281999.01, 0.29 −17150794.50 (15618685.51) −47997639.20 to 13696050.23, 0.27
80 000 −18733954.10 (17751810.67) −53790373.50 to 16322465.23, 0.29 −19600669.40 (17849926.33) −54854206.30 to 15652867.53, 0.27
90 000 −21075551.00 (19970792.40) −60514033.40 to 18362931.44, 0.29 −22050544.20 (20081167.14) −61710773.30 to 17609684.84, 0.27




Incremental net benefit 95% CI, p value Incremental net benefit 95% CI, p value
0 −2020.18 (558.61) −3123.38 to −916.98, <0.01 −2048.89 (946.17) −3917.66 to −180.11, 0.03
1500 −2226.59 (608.74) −3427.75 to −1023.38, <0.01 −2250.38 (1006.93) −4239.15 to −261.59, 0.03
2000 −2294.02 (645.94) −3569.69 to −1018.34, <0.01 −2317.54 (1039.73) −4371.10 to −263.98, 0.03
2500 −2362.48 (691.03) −3727.19 to −997.77, <0.01 −2384.70 (1077.94) −4513.73 to −255.67, 0.03
5000 −2704.77 (991.35) −4662.60 to −746.96, 0.01 −2720.52 (1331.67) −5350.69 to −90.34 0.04
10 000 −3389.38 (1735.70) −6817.21 to 38.45, 0.05 −3392.14 (2007.52) −7357.19 to 572.91, 0.09
20 000 −4758.57 (3339.13) −11353.01 to 1835.87, 0.16 −4735.40 (3560.87) −11768.45 to 2297.66, 0.18
30 000 −6127.77 (4972.26) −15947.50 to 3691.96, 0.22 −6078.65 (5181.15) −16311.90 to 4154.60, 0.24
40 000 −7496.98 (6613.14) −20557.26 to 5563.32, 0.26 −7452.72 (6820.82) −20893.66 to 6049.85, 0.28
50 000 −8866.17 (8257.13) −25173.19 to 7440.86, 0.29 −8765.16 (8468.63) −25491.49 to 7961.16, 0.30
60 000 −10235.37 (9902.70) −29792.22 to 9321.50, 0.30 −10108.42 (10120.60) −30097.54 to 9880.70, 0.32
70 000 −11604.56 (11549.16) −34413.03 to 11203.90, 0.32 −11451.68 (11774.98) −34708.34 to 11804.99, 0.33
80 000 −12973.76 (13196.19) −39034.94 to 13087.42, 0.33 −12794.93 (13430.88) −39322.15 to 13732.30, 0.34
90 000 −14342.96 (14843.59) −43657.60 to 14971.67, 0.34 −14138.19 (15087.81) −43937.98 to 15661.62, 0.35
100 000 −15712.16 (16491.26) −48280.77 to 16856.45, 0.34 −15481.44 (16745.45) −48555.23 to 17592.53, 0.36
*WTP for a one-point improvement on the WOMAC total score.
†Incremental net benefit (SE).
‡WTP for an additional QALY.
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of 200 WOMAC points, either: (1) assuming the added
surgery results in an improvement over non-operative
treatments only (167 WOMAC points), the cost is an
additional $2648, or (2) assuming non-operative treat-
ments result in an improvement over added surgery
(−199 WOMAC points), the ICER is −$2230, resulting
in paying more to achieve a worse outcome.
Additionally, for QALY, the sensitivity analysis suggests
either: (1) an ICUR of $17 010, where surgery costs an
additional $16 961 per QALY gained, or (2) an ICUR of
−$24 571 where surgery costs more and is less effective.
Uncertainty
The 95% CIs around our estimate of INB get wider as
the WTP value increases, suggesting that the more one
is willing to pay, the greater the uncertainty surrounding
the cost-effectiveness.
The uncertainty is also visually displayed on the cost-
effectiveness plane (figure 2). Although the majority of
the bootstrapped estimates suggest a greater improve-
ment in WOMAC score for the added surgery group,
very few represent a clinically important improvement
(200 points; figure 2A); whereas for QALY, about 60% of
the ICUR estimates favour a greater improvement for
the non-operative treatments only group (figure 2B). In
both cases, there is no uncertainty surrounding the cost
(surgery always costs more); therefore, decision makers
face the risk of paying more for a treatment with consid-
erable uncertainty that it will result in improved
outcome.
The probability of cost-effectiveness given this uncer-
tainty is visually displayed in the CEAC (figure 3). This
suggests that even if decision makers are willing to pay
$2000 or more for a one-point improvement on the
WOMAC total score (figure 3A; translating into
$400 000 to achieve a clinically important difference),
or $50 000 or more for an additional QALY (figure
3B), there is less than a 20% probability that added
surgery is cost-effective compared with non-operative
care only.
DISCUSSION
The results of the present analysis suggest that arthro-
scopic debridement and partial resection of degenera-
tive knee tissues performed in addition to optimised
physical and medical therapy for patients with knee OA
is not cost-effective compared with optimised physical
and medical therapy only, from both a healthcare payer
and societal perspective. This conclusion is driven by the
finding that although there is statistical uncertainty
about which treatment is more effective (ie, in our
sample a small improvement could favour either treat-
ment), the additional cost of surgery is not offset by
decreases in other healthcare costs, either direct or
indirect, associated with knee OA. Specifically, there
were no differences between groups in the use of non-
operative treatments, and a greater proportion of
patients in the surgery group reported taking time off
work at the 3-month follow-up.
Strengths of the present economic evaluation include
data collected from a prospective randomised trial with
frequent assessments over a 2-year follow-up and
minimal loss to follow-up or crossovers.10 This enabled a
rigorous trial-based economic evaluation with prospect-
ive collection of effectiveness and cost measures (includ-
ing indirect patient-reported costs), and the direct
measurement of utility scores from our study patients to
calculate QALYs. Further, using the NBR framework
allowed us to include potential interaction terms,
explore patient subgroups and evaluate the data for
influential outliers to provide us with a clearer
Figure 2 (A) The y-axis represents the incremental cost
(mean cost of arthroscopy group—mean cost of non-operative
group) in 2014 Canadian dollars. The x-axis represents the
mean difference in WOMAC total score at 2-year follow-up
between groups. The plotted values represent 1000 bootstrap
estimates of incremental cost-effectiveness ratios. (B) The
y-axis represents the incremental cost (mean cost of
arthroscopy group—mean cost of non-operative group) in
2014 Canadian dollars. The x-axis represents the mean
difference in quality-adjusted life years (QALYs) between
groups. The plotted values represent 1000 bootstrap
estimates of incremental cost-effectiveness ratios.
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understanding of the cost-effectiveness than would have
been possible by only looking at the incremental ratios.45
Limitations of this trial-based economic analysis may
include the inability to determine long-term cost-
effectiveness beyond 2 years of follow-up. However, previ-
ous research consistently shows that any small additional
benefits observed with arthroscopic surgery for degen-
erative knee conditions diminish by 1 year;10–14 16 there-
fore, we suggest it is unlikely for arthroscopy to become
cost-effective as time progresses. Reports of increased
risk for OA47–49 and earlier joint replacement50 after
meniscectomy should also be considered when evaluat-
ing long-term cost-effectiveness. As the present study was
designed to evaluate the cost-effectiveness of arthroscopy
in addition to non-operative care for patients with radio-
graphic knee OA (KL grade ≥2), results should be gen-
eralised accordingly. Conclusions about the clinical and
cost-effectiveness of the various non-operative treat-
ments, and the cost-effectiveness of arthroscopy for
patients without radiographic knee OA, should not be
drawn from the present data. Additionally, the present
sample does not include persons suspected by the
surgeon based on physical examination and history to
have a traumatic bucket handle meniscal tear (ie, acute
knee injury, swelling, acute loss of knee extension).
Unlike degenerative meniscal tears, bucket handle tears
are not common in knee OA and form a different
patient population. Importantly, the present results are
generalisable to the many patients with degenerative
knees receiving knee arthroscopy.24–26 Notably, operative
data from our trial suggest that, as anticipated, more
than 80% of patients had degenerative meniscal tears
that were partially resected.
Some suggest that arthroscopic debridement and
resection is beneficial for appropriately selected patients
with knee OA, such as those with minimal radiographic
changes and symptoms consistent with a torn meniscus.
Approximately, half of our sample would be classified by
accepted criteria as having mild OA (Kellgren-Lawrence
grade 2). Approximately, half of our sample reported
symptoms of catching and/or locking. We reported in
our original trial no added benefit of surgery among the
subgroup of patients with mild OA, or among the sub-
group of patients with symptoms of catching and/or
locking. Similarly, the present results suggest that arth-
roscopy is also not cost-effective for those subgroups of
patients compared with non-operative management.
The lack of clinical effectiveness in those subgroups is
consistent with meta-analysis of the randomised trials
evaluating arthroscopic partial meniscectomy in the
degenerative knee,17 including a sham controlled trial in
middle-aged patients with degenerative meniscal tears in
the absence of radiographic knee OA.18
To our knowledge, this is the first trial-based economic
evaluation to evaluate the cost-effectiveness of knee arth-
roscopy in addition to non-operative treatment strat-
egies. Lubowitz and Appleby32 reported the total
procedure costs for a range of arthroscopic procedures
and the change in utility score before and after surgery;
however, they did not compare arthroscopic surgery to
other interventions. Alternatively, Losina et al30 built a
probabilistic state-transition model to evaluate the cost-
effectiveness of arthroscopic surgery over a 10-year life
span for patients with knee OA. The model compared
immediate arthroscopic surgery, physical therapy and
delayed arthroscopic surgery (patients electing to
Figure 3 The y-axis represents
the probability that arthroscopy is
cost-effective compared with
non-operative treatment. The
x-axis represents the amount one
is willing to pay to achieve an
improvement in outcome ((A)
one-point improvement on
Western Ontario and McMaster
Universities Osteoarthritis Index
(WOMAC) total score, (B) one
additional quality-adjusted life
year).
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undergo surgery after 3 months of physical therapy).
The clinical and economic input parameters were
derived from a previous randomised trial12 (including
crossovers from physical therapy to surgery) using
patient-reported outcomes up to 6 months following
treatment, and from large cohort studies in the USA to
determine rates of progression of OA. The authors con-
clude that physical therapy alone is unlikely to be cost-
effective and suggest further research is required to
determine the cost-effectiveness of immediate arthros-
copy or arthroscopy following a course of physical
therapy. Although differences in study design, treatment
protocols and settings may contribute to their findings,
that study contrasts the present results in which there
were no differences in patient-reported outcomes,
healthcare resource use following treatment or product-
ivity losses between groups over a 2-year follow-up.
Several factors likely contribute to the continued fre-
quent use of arthroscopic debridement and resection of
degenerative knee tissues for knee OA.26 The unnecessary
use of MRI to diagnose degenerative meniscal tears, early
referral to orthopaedic surgeons, vested interests and the
evident placebo effect of surgery all likely contribute to
high patient and clinician expectations and demand for
the procedure. The variable increases in rates of arthros-
copy among different regions and previously observed
shifts in practice after publication of research findings
suggest that knowledge translation activities can affect
knee arthroscopy usage.19–26 We suggest that such activ-
ities should include cost-effectiveness data in addition to
clinical effectiveness data and target patients, all clinicians
involved in their care, as well as policymakers.
The preponderance of evidence suggests that arthro-
scopic debridement in the degenerative knee is not
superior to sham surgery, provides no sustained clinical
benefit over non-operative treatments and is associated
with potential harms.17 In addition to the lack of clinical
effectiveness, the present results suggest that arthro-
scopic debridement of degenerative articular cartilage
and resection of degenerative meniscal tears in addition
to non-operative treatment for knee OA is not an eco-
nomically attractive treatment option compared with
non-operative treatment only.
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